Elliot Stieglitz

List of Publications by Year
in descending order

59 papers	1,356 citations	394421 19 h-index	361022 35 g-index
62 all docs	62 docs citations	62 times ranked	2389 citing authors

#	Article	IF	Citations
1	The genomic landscape of juvenile myelomonocytic leukemia. Nature Genetics, 2015, 47, 1326-1333.	21.4	233
2	Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood, 2017, 130, 397-407.	1.4	112
3	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nature Communications, 2021, 12, 1334.	12.8	103
4	Genomic subtyping and therapeutic targeting of acute erythroleukemia. Nature Genetics, 2019, 51, 694-704.	21.4	97
5	Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nature Communications, 2017, 8, 2127.	12.8	75
6	Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood, 2015, 125, 516-524.	1.4	69
7	Genetic predispositions to childhood leukemia. Therapeutic Advances in Hematology, 2013, 4, 270-290.	2.5	68
8	International Interlaboratory Digital PCR Study Demonstrating High Reproducibility for the Measurement of a Rare Sequence Variant. Analytical Chemistry, 2017, 89, 1724-1733.	6.5	54
9	Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 629-636.	1.5	43
10	Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome. American Journal of Human Genetics, 2019, 104, 1223-1232.	6.2	43
11	Surface Proteomics Reveals CD72 as a Target for In Vitroâ€“Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL. Cancer Discovery, 2021, 11, 2032-2049.	9.4	37
12	International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia. Clinical Cancer Research, 2021, 27, 158-168.	7.0	35
13	Precision cancer monitoring using a novel, fully integrated, microfluidic array partitioning digital PCR platform. Scientific Reports, 2019, 9, 19606.	3.3	31
14	Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory Bâ€acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28718.	1.5	30
15	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro-Oncology, 2022, 24, 1845-1856.	1.2	30
16	Fusion driven JMML: a novel CCDC88Câ€“FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia, 2020, 34, 662-666.	7.2	27
17	Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatric Blood and Cancer, 2018, 65, e27034.	1.5	26
18	Molecular and phenotypic diversity of <I>CBL</I>-mutated juvenile myelomonocytic leukemia. Haematologica, 2022, 107, 178-186.	3.5	25

#	Article	IF	Citations
19	The impact of total body irradiationâ€based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2020, 67, e28079.	1.5	22
20	Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children. Genes Chromosomes and Cancer, 2019, 58, 723-730.	2.8	17
21	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discovery, 2021, 11, 1424-1439.	9.4	16
22	Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. Pediatric Blood and Cancer, 2019, 66, e27948.	1.5	13
23	Juvenile myelomonocytic leukemia in the molecular era: a clinicianâ€™s guide to diagnosis, risk stratification, and treatment. Blood Advances, 2021, 5, 4783-4793.	5.2	13
24	Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. Blood, 2014, 123, 1426-1427.	1.4	12
25	Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm. Leukemia, 2019, 33, 671-685.	7.2	12
26	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplantation, 2020, 55, 2160-2169.	2.4	11
27	ABVD Without Radiation for Newly Diagnosed Pediatric and Young Adult Patients With Hodgkin Lymphoma: A Single Center Retrospective Analysis of 28 Consecutive Patients. Journal of Pediatric Hematology/Oncology, 2018, 40, 290-294.	0.6	9
28	Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. Leukemia, 2021, , .	7.2	9
29	In Vitro-Selected Nanobody-Based Cellular Therapy Targeting CD72 for Treatment of Refractory B-Cell Malignancies. Blood, 2019, 134, 1337-1337.	1.4	8
30	Pulmonary Coccidiomycosis Masquerading as Refractory Metastatic Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2014, 36, e57-e60.	0.6	6
31	GermlineRRAS2mutations are not associated with Noonan syndrome. Journal of Medical Genetics, 2016, 53, 728-728.	3.2	6
32	Pediatric MDS: GATA screen the germline. Blood, 2016, 127, 1377-1378.	1.4	5
33	Complete Response to PD-1 Inhibition in an Adolescent With Relapsed Clear Cell Adenocarcinoma of the Cervix Predicted by Neoepitope Burden and APOBEC Signature. JCO Precision Oncology, 2020, 4, 1321-1332.	3.0	5
34	Targeting the Ras pathway in pediatric hematologic malignancies. Current Opinion in Pediatrics, 2021, 33, 49-58.	2.0	5
35	NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML. Journal of Pediatric Hematology/Oncology, 2021, 43, e808-e811.	0.6	5
36	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. Blood, 2018, 132, 1405-1405.	1.4	5

#	Article	IF	Citations
37	Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusionâ€“associated myeloid neoplasm. Blood Advances, 2022, 6, 1137-1142.	5.2	4
38	Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. Blood Advances, 2021, 5, 5507-5518.	5.2	4
39	MEK Inhibition Demonstrates Activity in Relapsed, Refractory Patients with Juvenile Myelomonocytic Leukemia: Results from COG Study ADVL1521. Blood, 2021, 138, 3679-3679.	1.4	4
40	JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1Î². Blood Advances, 2021, , .	5.2	3
41	Allosteric SHP2 Inhibitor RMC4550 Synergizes with Venetoclax in FLT3 and KIT Mutant Acute Myeloid Leukemia. Blood, 2021, 138, 2231-2231.	1.4	3
42	DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia: An International Collaborative Analysis and Development of a Common Diagnostic Platform. Blood, 2018, 132, 3093-3093.	1.4	2
43	Comprehensive Inflammatory Cytokine Profiling Identifies IL-8/CXCL8 As Elevated, Associated with Proliferative Features, and Independently Prognostic in Chronic Myelomonocytic Leukemia (CMML). Blood, 2016, 128, 109-109.	1.4	2
44	The Genomic Landscape of Childhood and Adult Acute Erythroid Leukemia. Blood, 2016, 128, 39-39.	1.4	2
45	Targeting M2-Tumor Associated Macrophages By Arginase-1 and PD-L1 in Regulating Juvenile Myelomonocytic Leukemia (JMML) Development and Relapse. Blood, 2021, 138, 1471-1471.	1.4	2
46	Inhibition of BTK and PI3KÎ´ impairs the development of human JMML stem and progenitor cells. Molecular Therapy, 2022, 30, 2505-2521.	8.2	2
47	Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia. Blood Advances, 2021, 5, 3587-3591.	5.2	1
48	Therapyâ€•related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature. Pediatric Blood and Cancer, 2022, 69, e29499.	1.5	1
49	Cytomorphologic features of pediatric-type follicular lymphoma on fine needle aspiration biopsy: case series and a review of the literature. Journal of the American Society of Cytopathology, 2022, 11, 281-294.	0.5	1
50	Dysregulation of the transcription factor runx1 in juvenile myelomonocytic leukemia. Experimental Hematology, 2017, 53, S51.	0.4	0
51	Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia. Blood, 2013, 122, 1526-1526.	1.4	0
52	Subclonal Mutations in SETBP1 Predict Relapse in Juvenile Myelomonocytic Leukemia. Blood, 2014, 124, 410-410.	1.4	0
53	RUNX1 Is a Candidate Transcriptional Effector in Juvenile Myelomonocytic Leukemia. Blood, 2016, 128, 2699-2699.	1.4	0
54	A Risk Stratified Treatment Algorithm for Patients with Juvenile Myelomonocytic Leukemia. , 2017, 14, .		0

#	Article	IF	Citations
55	Abstract 26: RUNX1 as a transcriptional target of activated Shp2 (PTPN11) in juvenile myelomonocytic leukemia. , 2017, , .		0
56	Germline GAB2 Mutations in Childhood Acute Lymphoblastic Leukemia. Blood, 2018, 132, 388-388.	1.4	0
57	DNA Methylation As a Biomarker of Outcome in JMML: An International Effort Towards Clinical Implementation. Blood, 2019, 134, 1693-1693.	1.4	0
58	Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome. Blood, 2020, 136, 35-36.	1.4	0
59	Genetic Alterations Precede DNA Methylation Changes in Juvenile Myelomonocytic Leukemia. Blood, 2020, 136, 19-20.	1.4	0